PT  - JOURNAL ARTICLE
AU  - Delius, G. W.
AU  - Powell, B. J.
AU  - Bees, M. A.
AU  - Constable, G. W. A.
AU  - MacKay, N. J.
AU  - Pitchford, J. W.
TI  - More prevalent, less deadly? Bayesian inference of the COVID19 Infection Fatality Ratio from mortality data
AID  - 10.1101/2020.04.19.20071811
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.04.19.20071811
4099  - http://medrxiv.org/content/early/2020/04/22/2020.04.19.20071811.short
4100  - http://medrxiv.org/content/early/2020/04/22/2020.04.19.20071811.full
AB  - We use an established semi-mechanistic Bayesian hierarchical model of the COVID-19 pandemic [1], driven by European mortality data, to estimate the prevalence of immunity. We allow the infection-fatality ratio (IFR) to vary, adapt the model’s priors to better reflect emerging information, and re-evaluate the model fitting in the light of current mortality data. The results indicate that the IFR of COVID-19 may be an order of magnitude smaller than the current consensus, with the corollary that the virus is more prevalent than currently believed. These results emerge from a simple model and ought to be treated with caution. They emphasise the value of rapid community-scale antibody testing when this becomes available.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external fundingAuthor DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesCode for reproducing the results of this report and plots of the results for other European countries can be found at https://github.com/gustavdelius/covid19model/